Nautilus Neurosciences
Bridgewater
About Nautilus Neurosciences
Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with relevant products and services that directly benefit those affected by neurological disorders. In the first half of 2010, Nautilus intends to launch a novel product, CAMBIA� (diclofenac potassium for oral solution). Nautilus is backed by Tailwind Capital, a leading private equity firm that invests in health care, business services and media/communications companies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $17.8M
- Funding stage: M&A
- Last round: Series A (Apr 2010)
- Website: nautilusneurosciences.com
- Phone: 9083937890
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/nautilus-neurosciences-2802365 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.